Marco Mielcarek

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:2675-8. 2012
  2. ncbi request reprint Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 129:381-91. 2005
  3. ncbi request reprint Effects of race on survival after stem cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:231-9. 2005
  4. pmc Identification and characterization of canine dendritic cells generated in vivo
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1286-93. 2007
  5. pmc Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:214-25. 2011
  6. pmc Pharmacological immunosuppression reduces but does not eliminate the need for total-body irradiation in nonmyeloablative conditioning regimens for hematopoietic cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 17:1255-60. 2011
  7. ncbi request reprint Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, Seattle, Washington University of Washington, Department of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:899-904. 2006
  8. ncbi request reprint Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 13:1160-8. 2007
  9. pmc Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1499-507. 2007
  10. ncbi request reprint Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 46:1251-60. 2005

Detail Information

Publications41

  1. pmc Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:2675-8. 2012
    ..In summary, transplantation of HLA-identical related G-PBMCs, compared with marrow, was associated with superior short-term and long-term DFS, and there was no evidence that this benefit was outweighed by GVHD-related late mortality...
  2. ncbi request reprint Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 129:381-91. 2005
    ..Patients with early-onset GVHD after non-myeloablative HCT from HLA-identical related donors might benefit from intensified primary immunosuppressive treatment...
  3. ncbi request reprint Effects of race on survival after stem cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:231-9. 2005
    ..We cannot exclude the possibility that the increased mortality risk among blacks after discharge from the transplant center might in part be related to unidentified sociocultural differences that influence medical care...
  4. pmc Identification and characterization of canine dendritic cells generated in vivo
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1286-93. 2007
    ..In summary, CD11c+/HLA-DR+/CD14-/DM5- cells obtained from canine peripheral blood have functional and morphologic characteristics similar to those of human myeloid DC...
  5. pmc Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:214-25. 2011
    ..In conclusion, our data fail to demonstrate MSC-mediated protection against GVHD and allograft rejection in this model...
  6. pmc Pharmacological immunosuppression reduces but does not eliminate the need for total-body irradiation in nonmyeloablative conditioning regimens for hematopoietic cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 17:1255-60. 2011
    ....
  7. ncbi request reprint Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, Seattle, Washington University of Washington, Department of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:899-904. 2006
    ..In conclusion, denileukin diftitox did not prevent, mitigate, or delay acute GVHD in this stringent and predictive (with respect to outcomes in human patients) hematopoietic cell transplantation model...
  8. ncbi request reprint Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 13:1160-8. 2007
    ..In the absence of innovative clinical trials, patients with early recurrence might wish to forego further interventions in favor of palliative care...
  9. pmc Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1499-507. 2007
    ..We conclude that within the limitations of a retrospective study, these results indicate that candidates for nonmyeloablative HCT without suitable related donors may expect similar outcomes with grafts from URDs...
  10. ncbi request reprint Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 46:1251-60. 2005
    ....
  11. pmc A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1088-92. 2011
    ..A larger registry study should be performed to provide more definitive information comparing outcomes with the 2 calcineurin inhibitors...
  12. pmc Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 115:1288-95. 2010
    ..009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy...
  13. ncbi request reprint Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, Seattle, WA, 98109 1024, USA
    Blood 102:756-62. 2003
    ..This "late-onset acute GVHD" should be taken into consideration in the design of prospective studies comparing GVHD resulting from the two types of transplantation procedures...
  14. pmc Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1463-6. 2010
    ..Hence, recipient statin treatment at the time of allogeneic HCT may decrease the risk of cGVHD in patients with cyclosporine-based immunosuppression, but at the expense of a compromised graft-versus-tumor effect...
  15. ncbi request reprint Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation
    Lauri Burroughs
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Transplantation 81:818-25. 2006
    ....
  16. pmc Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Christoph Kahl
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:2744-8. 2007
    ..The latter might benefit from cytoreductive treatment before HCT...
  17. pmc Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model
    Lauri Burroughs
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:4002-8. 2005
    ..In summary, both autologous and allogeneic AMD3100-mobilized PBMCs led to prompt and durable engraftment in dogs after 920 cGy TBI...
  18. pmc Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 13:423-32. 2007
    ....
  19. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013
    ..The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities...
  20. pmc Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation
    Won Sik Lee
    Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Biol Blood Marrow Transplant 17:465-75. 2011
    ..Although the MSCs displayed in vitro characteristics similar to those reported for MSCs from other species, their immunosuppressive qualities failed to sustain stable BM engraftment in vivo in this canine model...
  21. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  22. doi request reprint Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Transplantation 85:1023-9. 2008
    ..Late graft rejection after conditioning with 1 Gy of total body irradiation (TBI) was consistently seen in historical dogs given two postgrafting immunosuppressive drugs...
  23. pmc Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation
    Ron Ram
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 18:414-22. 2012
    ..We conclude that higher cyclosporine concentrations relatively early after nonmyeloablative HCT confer protection against aGVHD that translates into reduced risks of nonrelapse and overall mortality...
  24. ncbi request reprint Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 23:1993-2003. 2005
    ..This approach relied on graft-versus-tumor (GVT) effects for control of malignancy...
  25. pmc Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects
    Rainer Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
    Biol Blood Marrow Transplant 19:792-8. 2013
    ..These findings suggest that the immunologic mechanisms involved in acute GVHD might differ from those that initiate graft-versus-tumor effects...
  26. pmc Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target
    Masahiko Sato
    Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Transplantation 96:34-41. 2013
    ....
  27. pmc Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA and
    Blood 117:3214-9. 2011
    ..These results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronic GVHD is not simply the end stage of acute GVHD...
  28. pmc Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
    Mohamed L Sorror
    Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    JAMA 306:1874-83. 2011
    ..A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions...
  29. pmc Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
    Terry Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 14:531-7. 2008
    ..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD...
  30. ncbi request reprint Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation
    J Maciej Zaucha
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Br J Haematol 119:740-50. 2002
    ..In conclusion, our data suggest that major ABO-incompatibility is not a barrier to successful non-myeloablative HSCT...
  31. pmc Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig
    Scott S Graves
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109 1024, USA
    Transplantation 88:317-22. 2009
    ..To reduce or eliminate total body irradiation conditioning regimens, we have sought to develop canine specific reagents...
  32. pmc Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew R Rezvani
    Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington Medical Center, 1100Fairview Ave N, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:1594-601. 2011
    ..We conclude that change in serum albumin concentration from baseline to initiation of aGVHD treatment is an inexpensive, readily available, and predictive biomarker of GVHD severity and mortality after reduced-intensity allogeneic HCT...
  33. ncbi request reprint Radiation dose determines the degree of myeloid engraftment after nonmyeloablative stem cell transplantation
    Christoph Kahl
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:826-33. 2004
    ..These results suggest that the TBI dose determines the degree of myeloid engraftment by compromising the resident stem/progenitor cell compartment...
  34. pmc CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
    Margaret L Green
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 122:1316-24. 2013
    ..05; 95% CI, 0.9-1.3). This report demonstrates a modest reduction in early relapse risk after HCT associated with CMV reactivation in a large cohort of patients without a benefit in overall survival. ..
  35. ncbi request reprint CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Leuk Lymphoma 45:27-34. 2004
    ..This review discusses implications of CD34 cell dose adjustments in HLA-identical sibling G-PBMC transplantation and weighs the benefits and risks with respect to chronic GVHD, hematopoietic recovery, immune reconstitution and relapse...
  36. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, University of Washington, School of Medicine, Seattle, Washington 98109 1024, USA
    J Clin Immunol 22:70-4. 2002
    ..Enhancing graft-versus-tumor effects by virtue of postgrafting vaccination of recipients against tumor-specific antigens may help to use this transplant approach more effectively in the treatment of solid tumors...
  37. ncbi request reprint Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure?
    Norihiro Awaya
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:597-600. 2002
    ..In this review, we summarize reports on telomere shortening in stem cell transplantation recipients and report 2 cases in which graft failure is associated with significant telomere shortening...
  38. ncbi request reprint Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer Treat Rev 29:283-90. 2003
    ..Strategies aimed at inducing donor-specific tolerance and optimizing post-transplant immunosuppression may eventually eliminate the need for pre-transplant total body irradiation which is relevant for minimizing late toxicities...
  39. ncbi request reprint Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility
    Marco Mielcarek
    Br J Haematol 116:500-1. 2002
  40. ncbi request reprint Long-term engraftment and clonal dominance of donor-derived del(20q) hematopoietic cells after allogeneic stem cell transplantation
    Marco Mielcarek
    Blood 107:1732-3. 2006
  41. ncbi request reprint Is alloantigen expression by host epithelium required for acute graft-versus-host disease?
    Marco Mielcarek
    Nat Med 9:150-1; author reply 151. 2003